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The expression pattern of matrix-producing
tumor stroma is of prognostic importance
in breast cancer
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Abstract
Background: There are several indications that the composition of the tumor stroma can contribute to the
malignancy of a tumor. Here we utilized expression data sets to identify metagenes that may serve as surrogate
marker for the extent of matrix production and vascularization of a tumor and to characterize prognostic molecular
components of the stroma.
Methods: TCGA data sets from six cancer forms, two breast cancer microarray sets and one mRNA data set of
xenografted tumors were downloaded. Using the mean correlation as distance measure compact clusters with
genes representing extracellular matrix production (ECM metagene) and vascularization (endothelial metagene)
were defined. Explorative Cox modeling was used to identify prognostic stromal gene sets.
Results: Clustering of stromal genes in six cancer data sets resulted in metagenes, each containing three genes,
representing matrix production and vascularization. The ECM metagene was associated with poor prognosis in
renal clear cell carcinoma and in lung adenocarcinoma but not in other cancers investigated. Explorative Cox
modeling using gene pairs identified gene sets that in multivariate models were prognostic in breast cancer. This
was validated in two microarray sets. Two notable genes are TCF4 and P4HA3 which were included in the sets
associated with positive and negative prognosis, respectively. Data from laser-microdissected tumors, a xenografted
tumor data set and from correlation analyses demonstrate the stroma specificity of the genes.
Conclusions: It is possible to construct ECM and endothelial metagenes common for several cancer forms. The
molecular composition of matrix-producing cells, rather than the extent of matrix production seem to be important
for breast cancer prognosis.
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Background
Along with malignant cells, tumors contain a complex
microenvironment which consists of an extracellular
matrix (ECM) and a large variety of non-cancerous stromal
cells. The microenvironment is in constant interaction with
the cancer cells and becomes modified during tumor pro-
gression, exemplified by vascularization, remodeled ECM
and augmented tissue stiffness [1–3]. During remodeling,
the ECM undergoes a desmoplastic reaction generating a
fibrous tissue with many newly produced stromal proteins
[4] which can further promote cancer progression [5, 6].
The ECM is composed of a variety of components, with
fibroblast-produced collagens being one of the major pro-
teins [7]. High expression of collagens have for instance
been reported to associate with tumor metastasis in breast
cancer [8] and women with collagen-rich dense breasts
have an increased risk of developing breast cancer [9].
Stromal cells can also promote tumorigenesis by indu-
cing an angiogenic switch which may contribute to a
more aggressive phenotype of the tumor. This includes
increased endothelial cell proliferation and microvessel
density [10].
Global gene expression analyses have successfully
been used to subgroup tumors and identify molecular
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characteristics that are of prognostic value. The most
well-established example is perhaps the PAM50-based
classification of breast cancers [11]. In many cases the
profiles are based on gene expression presumably emanat-
ing from the cancer cells. However, there are also studies
that have identified gene signatures based on stromal
genes that have been indicated to predict clinical outcome
in breast cancer [12–14] and other tumor forms [15, 16].
In a recent study we identified genes specific for or highly
enriched in the stromal compartment of breast cancer tu-
mors using global RNA analyses of laser-microdissected tu-
mors followed by bioinformatics expansion by correlation
analyses using The Cancer Genome Atlas (TCGA) breast
cancer dataset [17]. When clustered, the genes could be
subgrouped in several compact clusters representing either
endothelial, immune response, or matrix-associated genes.
None of the signatures were strongly associated with
prognosis in univariate models. However, in a multivariate
analysis two signatures were prognostic with opposite
association with the hazard ratio, indicating that the
molecular composition of an immune response is more
important than the total extent of the response. This
raises the question if a similar concept holds for matrix-
related genes. Here we have tested the hypothesis that the
molecular composition of the matrix gene expression
profile of a tumor may be of prognostic importance.
Methods
Data sets
RNA-seq data for breast cancer, colon adenocarcinoma,
kidney renal clear cell carcinoma, head and neck cancer,
lung adenocarcinoma, lung squamous cell carcinoma, and
normal breast tissue were downloaded from the TCGA
data portal (Additional file 1: Table S1, [18]).
Breast cancer microarray data sets [19, 20] were down-
loaded from Array Express (Additional file 2: Table S2,
[21] and RNA-seq data of human breast cancer cell lines
grafted into mice were downloaded from GEO database
(Accession: GSE66744) [22].
Data analysis
All data analyses were performed with R. The TCGA
data were log2-transformed after addition of 1 to each
value. ECM and endothelial gene sets were expanded by
selecting genes from the TCGA breast cancer data set
that had a correlation coefficient above 0.84 with at least
one gene in the seeding sets defined as genes in our pre-
viously defined signatures 1 and 2 (ECM) and in signa-
ture 4 and 5 (endothelial) [17]. To obtain compact gene
clusters the correlation coefficients between all genes
were calculated and the gene with the lowest mean of
the correlation coefficients was removed from the set.
This procedure was repeated until all the genes in the
cluster had a mean correlation coefficient above 0.85.
The aggregated value of the obtained ECM and endothe-
lial metagenes for a tumor were calculated as the stan-
dardized mean of the log2 expression of all genes in the
signature.
For explorative survival analyses the log2 expression of
all genes in the expanded ECM set (Additional file 3:
Table S3) were tested pairwise in a multivariate Cox
proportional hazard model, stratified for ER and node
status, using the TCGA breast cancer data. The pairs
were ranked according to the p-value of the likelihood
ratio test of the models. Genes appearing more than
five times in the top 100 pairs were selected for inclusion
in “poor” and “good” prognosis signatures. The survival
package in R was used for all survival analyses. The R code
and the signatures defined in [17] are included as
Additional files 4, 5 and 6.
Histological analysis of TCGA breast tumors
Histological images of TCGA breast tumors stained with
hematoxylin and eosin were obtained from Cancer Digital
Slide Archive [23]. Tumor stroma patterns were classified
as “separated” or “mixed”. The stromal pattern was classi-
fied as “separated” when it was distinct and compactly or-
ganized surrounding a bulk tumorous structure whereas it
was classified as “mixed” when the pattern was typified by
disseminated stromal fibers mixed with the cancer cells
(Additional file 7: Figure S1). The tumor was classified
based on the dominating pattern. The amount of stroma
in a tumor section was furthermore estimated as low,
intermediate or high.
Tumor material for laser microdissection
Formalin-fixed specimens of tumors that had been re-
moved as part of standard care from patients that had
given informed consent were obtained from Skåne Uni-
versity Hospital, Malmö, and stored at 4 °C until analysis.
Ethical permission has been obtained from the local re-
search ethics committee (Regionala etikprövningsnämn-
den i Lund, Dnr 2009/658). The tumors were negative for
estrogen and progesterone receptors and had no ERBB2
(HER2) amplification according to the pathology reports.
The tumors analyzed had been classified as grade II or
grade III according to Nottingham histological grade.
Three of the tumors were reported to be invasive ductal
carcinoma, one ductal carcinoma in situ and one me-
dullary carcinoma. Specimens with sufficient amount of
stroma and stromal inflammation to enable RT-PCR ana-
lysis of laser-microdissected tumor compartments were
selected.
Tissue preparation, staining and laser microdissection
Sections of archived formalin-fixed paraffin-embedded
breast tumor samples (5 μm) were mounted onto poly-
ethylene terephthalate (PET) membrane slides (Leica
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Microsystems, Wetzlar, Germany) as described previously
[17] and stained with cresyl violet LCM staining kit
(Ambion, part of Thermo Fisher Scientific, Waltham, MA,
USA) to optimize RNA quality. Tumor compartments
were isolated with laser microdissection on a Leica
LMD6500 and collected in AllPrep RNA/DNA FFPE kit
lysis buffer (Qiagen, Hilden, Germany) with Proteinase
K (Additional file 8: Figure S2).
RNA extraction, reverse transcription and TaqMan RT-PCR
Total RNA was extracted and evaluated as described previ-
ously [17]. Quantive RT-PCR procedures were performed
using reagents from Applied Biosystems, part of Thermo
Fisher Scientific, Waltham, MA, USA. The High Capacity
RNA-to-cDNA kit was used for reverse transcription and
quantitative PCR was performed with TaqMan Gene ex-
pression master mix in QuantStudio 7 Flex Real-Time
PCR system (2 min 50 °C, 10 min 95 °C, 40 cycles of 15 s
95 °C followed by 1 min 60 °C). Predesigned assays for the
analyzed RNAs were obtained from the manufacturer
(Additional file 9: Table S4). Expression levels were nor-
malized to the expression of the reference genes ACTB
and UBC.
Results
Gene signatures for ECM and endothelial tissue
An initial aim was to identify gene signatures that would
indicate the amount of ECM-producing cells and endo-
thelial density in a tumor. To achieve this we utilized
the gene sets that we recently identified by global RNA
analysis of laser-microdissected breast cancer tumors [17].
We used the genes in the two ECM-related signatures to
expand the gene list by identifying all genes that in the
TCGA breast cancer RNA-seq data had a correlation coef-
ficient above 0.84 with at least one gene in the original
sets (Additional file 3: Table S3). We thereby assume that
we have gathered the genes that will have a conceivable
potential as markers for the amount of ECM-producing
cells such as fibroblasts. We thereafter reasoned that
genes that are highly correlated and form a compact
cluster may conceivably emanate from the same type of
cells. Therefore, the gene list was narrowed down to a
cluster defined as the genes for which the average of their
correlation coefficients with other genes in the cluster was
above 0.85.
Based on assumption that the tumor stroma may have
common characteristics across cancer forms the process
was reiterated for the TCGA colon adenocarcinoma,
head and neck squamous cell carcinoma, kidney renal
clear cell carcinoma, lung adenocarcinoma, and lung
squamous cell carcinoma data sets. The resulting gene sig-
natures for the cancer sets are shown in Table 1. Three
genes were present in the signatures from all cancer
sets, COL1A1, COL1A2, and COL3A1. These genes are
considered to be expressed mainly in fibroblasts, and
the fact they are highly correlated in all cancer forms
suggest that the expression levels of the genes may
represent fibroblast number in many different tumor
types. These genes were therefore defined as the ECM
metagene.
We took the same approach with the endothelial gene
sets. Also in this case three genes (CDH5, CXorf36, and
TIE1) were present in the final cluster in all six cancer
sets (Additional file 10: Table S5 and Table 2). These genes
were therefore defined as the endothelial metagene.
To investigate if the ECM and endothelial metagenes
are associated with each other, scatter plots were gener-
ated with the mean log2 expression level of the meta-
genes for each tumor as variables (Fig. 1). This revealed
a positive correlation between the sets in each tumor
form but the strength of the association varies with
correlation coefficients ranging from 0.34 in lung
adenocarcinoma to 0.78 in colon adenocarcinoma.
Association of ECM and endothelial signatures with
prognosis
There was no association with the magnitude of the
metagenes and prognosis in breast cancer, colon cancer
and head and neck cancer (Table 3A and B). However,
in kidney clear cell carcinoma and lung adenocarcinoma
Table 1 ECM gene signatures in TCGA cancer sets
BRCA COAD COAD cont HNSC KIRC LUAD LUSC
ADAM12 ADAM12 ITGA11 COL1A1 COL1A1 COL1A1 AEBP1
BNC2 AEBP1 LUM COL1A2 COL1A2 COL1A2 COL1A1
CDH11 ANTXR1 MMP2 COL3A1 COL3A1 COL3A1 COL1A2
COL1A1 BNC2 MSRB3 COL6A1 COL5A1 COL5A1 COL3A1
COL1A2 C10orf72 OLFML1 COL6A3 COL5A2 COL5A2 COL5A1
COL3A1 CCDC80 OLFML2B NID2 FAP COL6A3 COL6A3
COL5A1 COL1A1 PCOLCE OLFML2B THBS2 NID2
COL5A2 COL1A2 PDGFRB PDGFRB PDGFRB
COL6A3 COL3A1 SPARC POSTN SPARC
DACT1 COL5A1 THBS2 SPARC THBS2
FAP COL5A2 THY1 TIMP2







The signatures were defined by an iterative process. Starting with the
expanded ECM gene set (Additional file 3: Table S3) the gene with the lowest
mean value of the correlation coefficients of the log2 expression with the
genes in the set was removed from the set. The process was reiterated until
all genes had a mean correlation coefficient above 0.85
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the ECM metagene was associated with poor prognosis
and in kidney clear cell carcinoma the endothelial signa-
ture with good prognosis following adjustment for the
ECM set. For lung squamous cell carcinoma both meta-
genes were associated with poor prognosis but in a
multivariate model only the endothelial signature was
significant.
For breast cancer the association of the metagenes with
other prognostic factors was analyzed (Fig. 2). Both meta-
genes had higher expression values in ER-positive than
ER-negative tumors (Fig. 2a, d), suggesting that ER-
positive tumors are more stroma and vessel rich which
are in line with other studies [24–26]. We also found
that smaller tumors and node-positive tumors had slightly
Table 2 Endothelial gene signatures in TCGA cancer sets
BRCA COAD COAD cont HNSC KIRC KIRC cont LUAD LUSC
ARHGEF15 ARHGEF15 MMRN2 CD34 ARHGEF15 LDB2 ARHGEF15 CD93
CD34 BCL6B MYCT1 CDH5 BCL6B MMRN2 CD34 CDH5
CDH5 CALCRL PCDH12 CXorf36 CD34 MYCT1 CDH5 CXorf36
CXorf36 CD34 RHOJ ELTD1 CDH5 NOTCH4 CXorf36 TIE1
ELTD1 CD93 S1PR1 ESAM CLEC14A PCDH12 TIE1
ERG CDH5 SH2D3C RHOJ CXorf36 PLVAP
ESAM CLEC14A SHE TIE1 DLL4 ROBO4
LDB2 CXorf36 TEK ECSCR S1PR1




The signatures were defined by an iterative process. Starting with the expanded endothelial gene set (Additional file 10: Table S5) the gene with the lowest mean
value of the correlation coefficients of the log2 expression with the genes in the set was removed from the set. The process was reiterated until all genes had a
mean correlation coefficient above 0.85
Fig. 1 Correlation of ECM and endothelial gene signatures in different cancers. Scatter plots demonstrate mean log2 expression of ECM
and endothelial metagenes for individual tumors from the TCGA RNAseq data sets of a breast cancer, b colon cancer, c head and neck
cancer, d kidney renal clear cell carcinoma, e lung adenocarcinoma and f lung squamous cell carcinoma. The correlation coefficient is
shown in the figure for each data set
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higher expression levels of the ECM and endothelial
metagenes (Fig. 2b-c, e-f ). Since there was an associ-
ation with the gene signature level and these prognostic
markers, a multivariate Cox proportional model for the
breast cancer set was evaluated with the metagenes,
ER status, node status and tumor size as variables
(Table 3C). However, the metagenes were not associ-
ated with outcome in this model either.
To further delineate what the expression levels of the
ECM metagene may represent, the histology slides of
the breast cancer TCGA tumors were examined. The tu-
mors were categorized in two groups based on the major
pattern of stroma morphology (Additional file 7: Figure S1).
The groups represent 1) tumors where the stroma is clearly
separated from cancer cells and mainly form belts around
nodules of cancer cells and 2) tumors where the stroma is
largely mixed with the cancer cells. We found that tumors
with the mixed pattern had substantially higher expression
levels of the ECM signature (Fig. 3a). A visual quantification
of the total amount of stroma was also done and a weak as-
sociation of the level of the ECM metagene and the amount
of stroma was observed (Fig. 3b-c), but the association with
stroma type was more evident.
Prognostic ECM-associated gene sets
We recently found for immune response genes that com-
pact gene clusters, which are correlated to a substantial
degree, in a multivariate Cox model were highly associated
with outcome with opposing hazard ratios [17]. However,
in univariate models the clusters had no prognostic in-
formation. This implies that the molecular balance of
the immune response genes, rather than the extent of
the immune response, is of importance for prognosis. To
investigate if there is a similar phenomenon for ECM-
related genes we used the TCGA breast cancer cohort to
identify gene pairs that in multivariate models, stratified
for node and ER status, had opposing hazard ratios. We
thereafter selected the top 100 pairs, based on the p-value
of the likelihood ratio test of the model. To obtain signa-
tures associated with prognosis, genes that were present
in more than five of the top 100 pairs were selected. De-
pending on if the hazard ratio was >1 or <1 the gene was
classified in one of two sets, one associated with good and
one with poor prognosis in a multivariate model. The
genes in the sets are listed on top of Fig. 4.
The gene sets, quantified as the centered mean log2
expression level of the genes in the set, were evaluated
in univariate and multivariate Cox models for prognostic
association in several TCGA cancer sets (Fig. 4). Neither
set had a consistent association with prognosis in univari-
ate models except for kidney renal clear cell carcinoma
and lung adenocarcinoma where the poor prognosis set
was coupled to a worse prognosis, perhaps reflecting the
association of the ECM score with poor prognosis for
these cancer sets.
In the multivariate models the hazard ratios were mark-
edly shifted to larger magnitudes for both gene sets in all
TCGA data sets. The most striking effect was seen for the
TCGA breast cancer set, which is not surprising since this
set was used for training. To validate the breast cancer
data the same analysis was done on two breast cancer
microarray data sets (Fig. 4). Here the centered mean log2
value of the probe with maximal signal for each gene in
the set was used as a measure of the gene set. The Cox
model was stratified for ER and node status. Both sets
were associated with prognosis in a manner similar to the
TCGA cancer sets. Since the genes originally were se-
lected based on the association with stroma this suggests
there are characteristics of stroma that are important for
prognosis in breast cancer and that to some extent are
common for several cancer types.
To further delineate the importance in breast cancer
of individual genes in the gene sets, the standardized
log2 expression level of each individual gene was used in
a multivariate Cox model with the aggregated level of
Table 3 Cox proportional hazard models for six tumor types
using standardized mean values for the gene signature as
variables
Univariate Multivariate
HR p-val HR p-val
A) ECM
BRCA 0.961 0.784 1.002 0.991
COAD 0.823 0.387 0.735 0.397
HNSC 0.934 0.697 0.868 0.525
KIRC 1.321 0.014 1.434 0.003
LUAD 1.505 0.005 1.533 0.004
LUSC 1.268 0.047 1.144 0.331
B) Endothelial
BRCA 0.927 0.564 0.926 0.612
COAD 0.903 0.670 1.170 0.689
HNSC 1.032 0.851 1.122 0.591
KIRC 0.816 0.088 0.729 0.015
LUAD 1.018 0.898 0.915 0.561




Estrogen receptor 0.429 <0.001
Tumor size 2.363 0.014
Node status 2.120 0.004
In A and B the signatures were either tested in univariate models or together
in multivariate models stratified for age and stage. In C the model also
included estrogen receptor status (+/−), tumor size (<2 vs >2 cm), and node
status (+/−). All data are from TCGA cancer sets
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the opposing set as other variable. The analysis was done
for the two breast cancer microarray sets (Fig. 5). In
univariate models there were few cases when the 95 %
confidence interval of the hazard ratio did not include
1, although the genes in the good prognosis set gener-
ally had hazard ratios <1 (Fig. 5a) and the genes in the
poor prognosis set had ratios >1 (Fig. 5b). When adjust-
ing for the opposing metagene the magnitude of the
hazard ratio of essentially all genes was amplified and
in many instances it was significant. The 95 % confidence
intervals of the hazard ratios of P4HA3, SRPX2, DCN,
OMD, and TCF4 all excluded 1 in multivariate analysis in
both cancer sets. The other mRNAs were significant in
one of the microarray sets.
Expression of prognostic ECM-associated genes
To further analyze these genes their expression in breast
cancer tissue and accompanying normal tissue from the
TCGA data set was assessed (Fig. 6). For the genes in
the signature associated with improved prognosis all
genes were expressed at higher levels in normal breast
tissue (Fig. 6a), indicating that their down regulation
may be coupled to malignancy. For the genes associated
with poor prognosis three out of five were expressed at
lower levels in normal tissue. However, the interpret-
ation of this result is complicated by the fact that the
ECM metagene also is lower in normal tissue. Thus, the
lower expression of these genes may be a consequence
of fewer ECM-producing cells. Their expression was there-
fore normalized to the ECM metagene (Fig. 6c). Following
this adjustment only P4HA3 was higher in cancer tissue.
Our hypothesis was that all genes investigated are pri-
marily stromal and expressed in matrix-producing cells.
To further investigate this assumption we utilized data
from an elegant study where mRNAs from cancer cells
and stroma can be separated based on species differences
using human breast cancer cell lines grafted into mice
[22]. In all samples of grafts of either MDA-MB-231 or
MCF-7 cells, all genes in both prognostic sets were mark-
edly higher in the stroma (Fig. 7a-b). The only excep-
tion was ZEB1 which was at similar levels in the cancer
cells and in the stroma in the MDA-MB-231 tumors.
Fig. 2 Expression levels of ECM and endothelial metagene in TCGA breast cancer tumors. Graphs demonstrate mean log2 expression levels of
genes in the ECM and endothelial gene signatures in individual tumors grouped according to ER status (a and d), lymph node involvement
(b and e), and tumor size (c and f)
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Furthermore, all the mRNAs in the two prognostic sets
also had a high correlation coefficient with the ECM
metagene in the TCGA breast cancers further support-
ing their expression in stroma (Fig. 7d).
P4HA3 was the only mRNA that was expressed at
higher levels in cancer compared to normal breast tissue
following adjustment for the ECM metagene and it was
one of the genes that were significantly associated with
prognosis in the multivariate models in both microarray
sets. P4HA3 is a collagen-modifying enzyme causing
4-hydroxylation of prolines [27]. The reaction is also
catalyzed by the closely related proteins P4HA1 and
P4HA2. The hydroxylation is a prerequisite for efficient
collagen I triple helix formation. These genes were there-
fore compared regarding stromal enrichment and associ-
ation with prognosis. In the xenografted tumors both
P4HA1 and P4HA2 mRNA are found at similar levels in
cancer cells and in stroma, contrasting the stroma-specific
expression of P4HA3 (Fig. 8a). Furthermore, neither ECM
metagene-adjusted P4HA1 nor P4HA2 levels were higher
in breast cancer than in normal tissue, which also con-
trasts what was found for P4HA3 (Fig. 8b).
To further substantiate the stroma-specific expression
of P4HA3 we microdissected five breast cancer tumors
and analyzed the mRNA in the stroma and cancer cell
compartments (Fig. 8c). In the tumor P4HA3 mRNA
was detected in the stroma compartment in three out of
five tumors and it was undetectable in the cancer cell
compartment of all tumors. On the other hand, P4HA2
mRNA was detected at higher levels in the cancer cell
compartment of all tumors but one. We also analyzed
TCF4, which was found in the positive prognosis set,
and FAP, a marker for cancer associated fibroblasts. Both
genes were enriched in the stromal compartment of all
tumors investigated.
To analyze whether the stroma association of the P4HA
genes is a feature common across cancer types the correl-
ation coefficients of the P4HA mRNAs with the ECM
metagene was analyzed in six TCGA sets (Fig. 8d). In all
cancers P4HA3 was the gene whose expression had the
highest correlation coefficient with the ECM metagene.
In addition, we assessed the association of the expres-
sion levels of P4HA genes with prognosis using the TCGA
and the two microarray breast cancer sets (Fig. 8e). The
P4HA mRNAs were to a varying extent associated with
poor prognosis in all sets. However, when adjusting for
the ECM metagene by including it in a multivariate
model, the magnitude of the hazard ration was enhanced
only for P4HA3.
Discussion
In this study we have taken an approach to utilize RNA-
seq data to obtain an estimation of the amount of stroma
and vascularization in a tumor and to analyze if these
estimates or the mRNA composition of the stroma are
associated with prognosis. Through this approach we
Fig. 3 Expression levels of the ECM metagene in breast cancer tumors related to stroma morphology. The mean log2 expression levels of genes in
the ECM gene signature are shown for TCGA breast tumors categorized as predominantly having separated (S) or mixed (M) stromal pattern (a), or
based on a score of the total amount of tumor stroma (b). c demonstrates the expression level with respect to both stroma type and stroma score
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have identified two gene sets, which in breast cancer
when adjusted for each other are associated with poor
and good prognosis, respectively. This highlights poten-
tial genes that may determine the contribution to ma-
lignancy of the tumor stroma.
A tumor consists of a wide range of cell types. It is
conceivable that in many instances cells of the same type
have a set of genes that are fairly specific for the type.
Unless they are differentially regulated the expression of
such genes would be expected to be highly correlated
and related to the amount of the cells in the specimen.
This reasoning was the basis for the search for compact
clusters of genes using the mean correlation coefficient
of the log2 expression as a similarity measure. For the
ECM-related genes the size of the cluster varied with
tumor type. The common genes were all collagens indi-
cating that it represents the amount of collagen-produ-
cing cells such as fibroblasts or other mesenchymal cells.
This is further supported by other genes that correlated
closely in many cancer forms such as FAP, PDGFRB,
THBS2 and VCAN which are also markers for matrix-
producing cells and in some cases also for cancer-
associated fibroblasts [28–30].
The largest ECM cluster was obtained for the colorectal
adenocarcinoma data set whereas the smallest cluster was
seen for kidney renal clear cell carcinoma. This could be
due to a higher stroma fraction in colorectal adenocarcin-
omas which would conceivably result in higher signal to
noise ratios for the stromal genes and consequently larger
correlation coefficients. In fact, the renal clear cell carcin-
omas had the lowest expression level of the ECM meta-
gene (Additional file 11: Figure S3A). On the other hand,












Fig. 4 Hazard ratios of gene sets with opposing prognostic association
in different cancer data sets. Lines represent confidence intervals
(95 %) from multivariate Cox proportional hazard analyses using
mean log2 expression of the genes in the prognostic ECM gene
signatures (listed on top of the figure) stratifying for age and stage.
Red lines and font represent the signature associated with poor
prognosis and blue lines and font the signature associated with
good prognosis when both signatures are evaluated in a multivariate
Cox model. For the TCGA breast cancer (BRCA, which was used for
training) and the breast cancer microarray sets (GEOD21653 and
EMTAB365) the model was adjusted for node and ER status. The
TCGA data sets are colon adenocarcinoma (COAD), head and neck
squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma
(KIRC), lung adenocarcinoma (LUAD) and lung squamous cell
carcinoma (LUSC)
Fig. 5 Association of individual genes in the prognostic signatures
with prognosis in breast cancer microarray sets. The association with
prognosis of the expression of individual genes in the good (a) and
poor (b) prognosis signatures was analyzed using Cox proportional
hazards modeling. Figures demonstrate 95 % confidence interval of
the hazard ratio for the standardized log2 mRNA expression of
indicated genes in a univariate (dark colors) or multivariate (bright
colors) model. In the latter case the aggregated value of the poor
prognosis signature (a) or good prognosis signature (b) was used as
additional variable in the model
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endothelial metagene (Additional file 11: Figure S3B), and
here the compact cluster, together with colorectal adeno-
carcinoma, contained the largest number of genes among
the cancer types. Thus, there may be a relation between
the expression level of the metagene and the number of
genes that will be found in a compact cluster. Kidney renal
clear cell carcinomas are frequently highly vascularized
due to deletion or inactivation of the VHL suppressor
gene which results in upregulation of hypoxia-inducible
factors and angiogenic factors such as VEGF [31]. Our
data are in line with this.
To obtain general signatures for the stromal components
the final metagenes were based on the clusters obtained
from six separate cancer forms. This will conceivably in-
crease the likelihood for obtaining metagenes stable over
several cancer forms. The requirement reduced the num-
ber of genes in the ECM and endothelial signatures to
three in each set. The levels of the ECM and endothelial
metagenes correlated positively in all cancer forms to vary-
ing extent. Thus, there may be interdependency between
the ECM production and the amount of endothelial cells
in a tumor or one may be influenced by the other. It has
for instance been shown that ECM-producing fibroblasts
promote endothelial lumen formation [32].
The tumor specimen taken for RNA analysis may
contain surrounding non-tumor tissue. This could po-
tentially influence both the extent and type of mRNA
derived from stroma and thereby the interpretations of
for instance survival analyses and correlations with
clinicopathological parameters of the metagenes. How-
ever, there was an association of the ECM metagene
with the stroma pattern in the tumor (Fig. 3) suggesting
that at least the ECM metagene to some extent repre-
sents features of the intratumor stroma. Using the mean
log2 expression of these genes as indicator for the amount
of ECM-producing cells and endothelial cells no associ-
ation with prognosis could be detected in most cancer
types analyzed. However, for both renal clear cell
carcinoma and lung adenocarcinoma higher levels of
the ECM score was associated with worse prognosis.
Furthermore, when adjusting for the ECM signature,
the endothelial set was associated with an improved
prognosis in renal clear cell carcinoma. Thus, for a
given level of stroma-producing cells an increased
Fig. 6 Expression of genes in prognostic signatures in breast cancer versus normal tissue. The mRNA levels of the genes in the good (a) and
poor (b) prognosis signatures in TCGA breast cancer tumors and normal breast tissue from the same patient. Since the ECM metagene is expressed at
higher levels in cancer tissue the levels of the genes in (b) were normalized to the mean log2 value of the ECM metagene (c). The p-value of a t-test
comparing the two groups is indicated in each figure
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vascularization may indicate a better prognosis for
kidney renal clear cell carcinoma.
For breast cancer no association for the ECM metagene
with prognosis was observed, neither in univariate nor
multivariate models when adjusting for other prognostic
factors. This is analogous to what we have also seen for
immune-related sets [17]. However, as for the immune
genes it was possible to identify ECM gene sets that when
evaluated in a multivariate Cox model had opposite asso-
ciations with prognosis. The sets had a similar association
with prognosis in multivariate models in several cancer
forms. In two breast cancer microarray sets the pattern
was the same as in the TCGA breast cancer set with the
two gene signatures being not so strongly associated with
prognosis in univariate Cox models but being clearly asso-
ciated with prognosis in the multivariate setting. Thus, the
molecular composition of the stroma-producing cells may
be more important for breast cancer prognosis than the
extent of stroma production in the tumor.
In terms of individual genes in the prognostic signa-
tures TCF4 was perhaps the most striking example in
the set associated with improved prognosis. Its association
with prognosis was not so strong in a univariate model but
when adjusting for the poor prognosis set it had a clear as-
sociation with improved prognosis. This may be somewhat
counterintuitive given the vast number of reports that have
linked β-catenin/TCF with oncogenic effects following the
discovery of Tcf as a component in the mediation of malig-
nancy induced by APC deletion [33]. However, the data
shown here represented by the high correlation coefficient
between TCF4 and the ECM metagene, the higher expres-
sion of TCF4 in the stroma of both xenografted tumors
and laser-microdissected breast cancer tumors indicate
that in breast cancer the bulk of TCF4 mRNA emanates
from matrix-producing cells. Here its expression may actu-
ally oppose a malignant development of the tumor given
its association with improved prognosis. Such an assump-
tion is supported by the fact that TCF4 is found at higher
levels in normal than in breast cancer tissue in the TCGA
set and in another material [34].
For the genes in the poor prognosis set P4HA3 was as-
















Fig. 7 Expression of prognostic signature genes in tumor stroma. The mRNA expression data from the xenografted tumors in [22] were downloaded.
The RPKM data of a gene was divided by the total sum of RPKM in the sample and multiplied by 100,000. The normalized value was log2 transformed
following addition of 1. The resulting values for the genes in the good (a) or poor (b) prognosis in each tumor are depicted. As a comparison, values
of selected house-keeping genes or cancer-related genes are shown in (c). The correlation coefficients for each gene in the prognostic signatures with
the ECM metagene in TCGA breast cancers are shown in (d)
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in both microarray sets. It was also the only mRNA in
the poor prognosis signature that after normalization
to the ECM metagene was expressed at higher levels
in cancer than in normal tissue. The P4HA proteins
catalyze a 4-hydroxylation on prolines in collagen. P4HA1
and P4HA2 in the cancer cells have been shown to be crit-
ical for breast cancer cell line collagen deposition, invasion
and metastasization [35]. They are also induced in fibro-
blasts by hypoxia and there contributes to production of a
matrix that promotes breast cancer cell migration [36].
The P4HA-mediated reaction takes place intracellularly
and it would therefore be expected that the magnitude of
P4HA gene expression would primarily correlate with col-
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Fig. 8 Expression and prognostic association of P4HA gene mRNAs. The expression of P4HA1 and P4HA2 was calculated in the stroma and cancer
cells using the xenograft data (a) and in breast cancer and normal breast tissue normalized to the ECM metagene using the TCGA data (b). The
P4HA3 data, also shown in Figs. 6 and 7 are included for comparison. Five breast cancer tumors were laser-microdissected and the mRNA levels
of indicated genes were analyzed in the cancer cell and stroma compartments (c). The correlation coefficients of P4HA1, P4HA2, and P4HA3 with
the ECM metagene in six different TCGA cancer sets were calculated (d). The hazard ratios of the standardized log2 mRNA expression of the P4HA
genes were estimated using Cox proportional hazards model (e). The lines indicate 95 % confidence intervals of the hazard ratios in univariate models
(dark colors) or multivariate models (bright colors) in which the standardized ECM metagene was included as variable. All models were stratified for
node and ER status
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P4HA3. P4HA3 is the only P4HA gene that seems to be
selectively expressed in the stroma of tumors. P4HA3 is
also the only P4HA gene whose association with poor
prognosis in a Cox model is enhanced upon adjustment
for an ECM metagene. This highlights P4HA3 expression
as a marker for malignant stroma and for stroma that con-
tributes to poor prognosis. It is in this context of interest
to note that P4HA3 has been identified as an important
contributor to TGFβ-mediated pulmonary fibrosis [37].
Our data indicate an additional role for P4HA3 in the
matrix-producing cells in the tumor stroma.
Conclusions
In conclusion this study indicates that the amount of
stroma or endothelial tissue is not a strong prognostic
factor in breast cancer. However, the molecular balance
in the matrix-producing cells is associated with prognosis.
Here we provide indications that the expression levels
of TCF4 and P4HA3 in the stroma are associated with
prognosis. They may therefore contribute to (P4HA3) or
suppress (TCF4) the malignant contributions of stroma.
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